Mitomycins: A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.Porfiromycin: Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Pamphlets: Printed publications usually having a format with no binding and no cover and having fewer than some set number of pages. They are often devoted to a single subject.Drug Labeling: Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.Patient Education as Topic: The teaching or training of patients concerning their own health needs.Formularies as Topic: Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).Tertiary Healthcare: Care of a highly technical and specialized nature, provided in a medical center, usually one affiliated with a university, for patients with unusually severe, complex, or uncommon health problems.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Genital Diseases, Female: Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Fallopian Tube Neoplasms: Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Administration, Intravesical: The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Urinary Bladder: A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Syringes: Instruments used for injecting or withdrawing fluids. (Stedman, 25th ed)Thermoluminescent Dosimetry: The use of a device composed of thermoluminescent material for measuring exposure to IONIZING RADIATION. The thermoluminescent material emits light when heated. The amount of light emitted is proportional to the amount of ionizing radiation to which the material has been exposed.Polymethyl Methacrylate: Polymerized methyl methacrylate monomers which are used as sheets, moulding, extrusion powders, surface coating resins, emulsion polymers, fibers, inks, and films (From International Labor Organization, 1983). This material is also used in tooth implants, bone cements, and hard corneal contact lenses.Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.Filtering Surgery: A surgical procedure used in treatment of glaucoma in which an opening is created through which aqueous fluid may pass from the anterior chamber into a sac created beneath the conjunctiva, thus lowering the pressure within the eye. (Hoffman, Pocket Glossary of Ophthalmologic Terminology, 1989)Trabeculectomy: Any surgical procedure for treatment of glaucoma by means of puncture or reshaping of the trabecular meshwork. It includes goniotomy, trabeculectomy, and laser perforation.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.BooksPublishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Liver Neoplasms: Tumors or cancer of the LIVER.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Chemotherapy, Cancer, Regional Perfusion: Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.Infusions, Intra-Arterial: Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.Hepatic Artery: A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.Keratomileusis, Laser In Situ: A surgical procedure to correct MYOPIA by CORNEAL STROMA subtraction. It involves the use of a microkeratome to make a lamellar dissection of the CORNEA creating a flap with intact CORNEAL EPITHELIUM. After the flap is lifted, the underlying midstroma is reshaped with an EXCIMER LASER and the flap is returned to its original position.Lasers, Excimer: Gas lasers with excited dimers (i.e., excimers) as the active medium. The most commonly used are rare gas monohalides (e.g., argon fluoride, xenon chloride). Their principal emission wavelengths are in the ultraviolet range and depend on the monohalide used (e.g., 193 nm for ArF, 308 nm for Xe Cl). These lasers are operated in pulsed and Q-switched modes and used in photoablative decomposition involving actual removal of tissue. (UMDNS, 2005)Myopia: A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness.Refraction, Ocular: Refraction of LIGHT effected by the media of the EYE.Surgical Flaps: Tongues of skin and subcutaneous tissue, sometimes including muscle, cut away from the underlying parts but often still attached at one end. They retain their own microvasculature which is also transferred to the new site. They are often used in plastic surgery for filling a defect in a neighboring region.Optometry: The professional practice of primary eye and vision care that includes the measurement of visual refractive power and the correction of visual defects with lenses or glasses.Book Reviews as Topic: Critical analyses of books or other monographic works.Ophthalmology: A surgical specialty concerned with the structure and function of the eye and the medical and surgical treatment of its defects and diseases.Book ReviewsBibliography of Medicine: A list of works, documents, and other publications on medical subjects and topics of interest to the field of medicine.Spiders: Arthropods of the class ARACHNIDA, order Araneae. Except for mites and ticks, spiders constitute the largest order of arachnids, with approximately 37,000 species having been described. The majority of spiders are harmless, although some species can be regarded as moderately harmful since their bites can lead to quite severe local symptoms. (From Barnes, Invertebrate Zoology, 5th ed, p508; Smith, Insects and Other Arthropods of Medical Importance, 1973, pp424-430)Newspapers: Publications printed and distributed daily, weekly, or at some other regular and usually short interval, containing news, articles of opinion (as editorials and letters), features, advertising, and announcements of current interest. (Webster's 3d ed)
PVOD may occur in patients with associated diseases such as HIV, bone marrow transplantation, and connective tissue diseases. ... PVOD has also been associated with several chemotherapy regimens such as bleomycin, BCNU, and mitomycin. Chloe Temtchine, ...
April 2009). "Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the ... but this largely depends upon patient preference, age of patient, renal function, and the site of the disease. A combination of ... with improved overall quality of life versus patients undergoing radical cystectomy with urinary reconstruction. These patients ... In this patients first receive chemotherapy in 3 or 4 cycles, and after that proceed to major surgery. In a number of meta- ...
Survival and cure rates are excellent, and many patients are left with a functional sphincter. Some patients have fecal ... Current chemotherapy consists of continuous infusion 5-FU over four days with bolus mitomycin given concurrently with radiation ... More than half of the anal-cancer patients studied were current smokers at the time of diagnosis, as compared to a smoking rate ... Human papillomavirus: Examination of squamous cell carcinoma tumor tissues from patients in Denmark and Sweden showed a high ...
Patients stay in the hospital as long as three weeks to give the immune system time to recover to a point where there is no ... Other cytotoxic antibiotics are anthracyclines, mitomycin C, bleomycin, mithramycin. Antibodies are sometimes used as a quick ... The patient suffers from fever, joint pain, and erythema that can be soothed with the use of steroids and analgesics. Urticaria ... Because of a high immunogenicity of polyclonal antibodies, almost all patients have an acute reaction to the treatment. It is ...
"Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase ... which qualified patients for inclusion in urinary bladder cancer clinical trials. In addition, he was Founding Director of the ... "Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients' Tumors: Consensus Recommendations". Cancer ...
Patients are instructed to call immediately for pain that cannot be controlled with over the counter pain medication or if ... Marey, H M; S S Mandour; A F Ellakwa (Oct 2012). "Subscleral Trabeculectomy with Mitomycin-C Versus Ologen for Treatment of ... Rarely general anesthesia will be used, in patients with an inability to cooperate during surgery. An initial pocket is created ... A Cochrane review sought to compare the effectiveness of fornix-based versus limbal-based conjunctival flaps for patients ...
Patients homozygous for null-mutations in this gene have an earlier onset of anaemia than those with mutations that produce an ... Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H (1999). "Resistance to mitomycin C requires direct interaction between the Fanconi ... In particular many patients develop megaloblastic anaemia around the age of 7, with this macrocytosis being the first ... For example, patients with homozygous null-mutations in FANCA have a markedly increased susceptibility to acute myeloid ...
Most patients will be able to self-administer the drug after appropriate training. Patients with severe renal impairment should ... mitomycin C. Neumega should not be given in these cases. In studies with rats and rabbits treated chronically, Oprelvekin ... Patients with known hypersensitivity to Oprelvekin itself or any other ingredient. Patients with severe or decompensated heart ... Severe impairment has led to an increased number of patients with reduced hemoglobin due to dilutional anemia. Patients with ...
Some patients are given mitomycin into the bladder either as a one-off dose in the immediate post-operative period (within 24 ... In such patients, a bowel loop is often used to create either a "neo-bladder" or an "ileal conduit" which act as a place for ... In patients with evidence of early muscular invasion, radical curative surgery in the form of a cysto-prostatectomy usually ... of patients having more than one tumor at diagnosis. The pattern of growth of TCCs can be papillary, sessile, or carcinoma-in- ...
In cases of patients who still have residual disease after receiving the procotol, they should undergo salvage APR (abdomino- ... Nigro protocol is the pre-operative use of chemotherapy with 5-fluorouracil and mitomycin and medical radiation for squamous ... Specifically, in the protocol, the patient receives 60 Gy of radiation over a five week period, as well as continuous ... administration of fluorouracil for the first four days and on days 29-32, with the mitomycin administered on the first day of ...
Achakzai, Jamila (Feb 5, 2012). "NOORI treats more than 80% cancer patients". The News. Khurshid, S.J (December 7, 2005). " ... Randomized clinical trial of radiotherapy combined with Mitomycin-C. Randomized Multi Center study of radiotherapy in the ... The hospital is providing treatment facilities to about 40,000 patients from Islamabad, Hazara, Jhelum, Sargodha, Azad Kashmir ... to caterer Patients from Islamabad and adjoining areas. NORI is the first institute which has been recognized by College of ...
The life span of patients with such mutations is often around 1-2 years. One Cockayne syndrome (CS) type II patient designated ... These polymorphisms may have differential effects on platinum and mitomycin damage. ERCC1 protein expression is reduced or ... A few patients with severely disabling ERCC1 mutations that cause cerebro-oculo-facio-skeletal syndrome (COFS) have been ... This has been suggested for patients with gastric, ovarian, colorectal and bladder cancers. In Non-small cell lung carcinoma ( ...
The patient spends only a few hours in the hospital with minimal preoperative preparation. The average duration of the surgery ... Kersey, J. P.; Vivian, A. J. (Jul-Sep 2008). "Mitomycin and amniotic membrane: a new method of reducing adhesions and fibrosis ... After surgery, the patient should expect soreness and redness. In cases of re-operations, more pain is expected. Resection of ... The likelihood that the eyes will stay aligned over the longer term is higher if the patient is able to achieve some degree of ...
The patient may also have one or all of the following exams: Gastroscopic exam is the diagnostic method of choice. This ... as well as mitomycin C, and more recently cisplatin and taxotere, often using drugs in various combinations. The relative ... In a study of open-access endoscopy in Scotland, patients were diagnosed 7% in Stage I 17% in Stage II, and 28% in Stage III. A ... However, in a high-risk population in the Valdivia Province of southern Chile, only 5% of patients were diagnosed in the first ...
Only male patients with Fanconi anemia have ever been linked to FANCB mutations, and they make up about 4% of cases. The FANCB ... mitomycin c and melphalan. Within the Fanconi anemia core complex, FANCB has an obligate interaction with FAAP100 and FANCL, to ...
However, some patients have "unassigned" Fanconi Anemia where no mutations in the known FA genes can be found. Mutations in ... A deficiency of FAN1 increases in vitro sensitivity to cisplatin and mitomycin C, two crosslinking agents FAN1 is also able to ... repair mitomycin C induced double strand breaks. Germline mutations in the FAN1 gene can cause hereditary colorectal cancer due ...
A donor patient acquires one defective gene copy and one normal, and only one of these two copies is used for reproduction. By ... The extracted inner cell mass was cultured on fibroblasts treated with mitomycin-c in a medium containing serum and conditioned ... Patients followed 2-3 years after AST-OPC1 administration showed no evidence of serious adverse events associated with the ... In addition, this will allow the generation of ES cell lines from patients with a variety of genetic diseases and will provide ...
In addition, Fanconi patients normally are born with a variety of birth defects. A good number of Fanconi patients have kidney ... Assembly is activated by replicative stress, particularly DNA damage caused by cross-linking agents (such as mitomycin C or ... Many patients do not reach adulthood. The overarching medical challenge that Fanconi patients face is a failure of their bone ... Many patients eventually develop acute myelogenous leukemia (AML). Older patients are extremely likely to develop head and neck ...
... an infection of the lungs not related to the medicinal drugs the patient is taking. But if the patient is taking such a ... mitomycin C, busulfan, cyclophosphamide, chlorambucil, and nitrosourea (e.g., carmustine). Also, some medicinal drugs used in ... Most patients with AIPT respond well to the withdrawal of amiodarone and to the addition of corticosteroid treatment, which is ... Lung symptoms in a patient who is taking a medicinal drug that can cause pulmonary toxicity should not automatically lead to a ...
Due to the increased availability of new chemotherapies developed for colon and colorectal cancer patients, some patients have ... Chemotherapy (typically the agent Mitomycin C) may be infused directly into the abdominal cavity after cytoreductive surgery to ... Although some surgical procedures may be rather extensive, patients can and do recover from surgery, and the majority of these ... In situations where surgery is not required immediately, patients can be monitored via CT scans, tumor marker laboratory tests ...
BSA-dosed patients were treated for a total of 680 months while dose-adjusted patients were treated for a total of 791 months. ... Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA. Most chemotherapy is delivered intravenously, although a ... Patients frequently fail to understand its limitations. In one study of patients who had been newly diagnosed with incurable, ... As more than half of cancer patients are elderly, this adverse effect is only relevant for a minority of patients. A study in ...
"Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients". Proc. Natl. Acad. Sci. U.S.A ... and polymerase eta-mediated error-prone removal of mitomycin C interstrand cross-links". Mol. Cell. Biol. 23 (2): 754-61. doi: ... "The role of polymerase eta in somatic hypermutation determined by analysis of mutations in a patient with xeroderma pigmentosum ...
Three patients received a low dose, three a middle dose and three a high dose. Five of the nine patients, or 55.6%, experienced ... evaluate the safety and optimal dose of Cavatak as a monotherapy and in combination with the standard of care drug mitomycin C ... CALM's Primary Endpoint, reached in September 2013, was 10 patients from a total of 54 evaluable patients experiencing immune- ... "First Patient Enrolled in Viralytics' Phase I Melanoma Cancer Trial With Cavatak" (PDF). asx.com.au. 24 May 2007. Retrieved 4 ...
Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no ... Cillino, S; Casuccio A; Di Pace F; Cagini C; Ferraro LL (Mar 2016). "Biodegradable collagen matrix implant versus mitomycin-C ... A 2003 study of patients in an HMO found half failed to fill their prescriptions the first time, and one-fourth failed to ... Patients with such condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially ...
Some methods prompt production with UV radiation, Mitomycin C, or heat shock. UV radiation and Mitomycin C are used because the ... Potentially, the bacteriocins could be produced by bacteria intentionally introduced into the patient to combat infection. In ... Saito H, Watanabe T, Osasa S, Tado O (1979). "Susceptibility of normal and tumor cells to mycobacteriocin and mitomycin C". ...
Competence in S. pneumoniae is induced by DNA-damaging agents such as mitomycin C, fluoroquinolone antibiotics (norfloxacin, ... "The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study". BMC Infectious ... pneumoniae against the bactericidal effect of mitomycin C.[17] Michod et al.[18] summarized evidence that induction of ...
Detailed drug Information for mitomycin Intravenous. Includes common brand names, drug descriptions, warnings, side effects and ... has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during therapy with mitomycin, ... In some patients, this may occur weeks or even months after mitomycin is given. Tell the doctor or nurse right away if you ... The dose of mitomycin will be different for different patients. Follow your doctors orders or the directions on the label. The ...
Professional guide for MitoMYcin (Ophthalmic). Includes: pharmacology, pharmacokinetics, contraindications, interactions, ... Patient Education. • Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During ... Mitomycin is not cell cycle specific but has its maximum effect against cells in late G and early S phases (Perry 2012). During ... Hypersensitivity to mitomycin or any component of the formulation; pregnancy. Dosing: Adult. Glaucoma surgery (adjunctive ...
Mitomycin C in patients with gynecological malignancies.. [Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav ... Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast ... Mitomycin, European Pharmacopoeia (EP) Reference Standard C15H18N4O5 ... This review presents and discusses the current treatment options with MMC in patients with breast, cervical, and vulvar ...
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis. The safety and scientific validity of this study is the ... Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis. ... Drug Information available for: Mitomycin Mitomycins Genetic and Rare Diseases Information Center resources: Primary Sclerosing ... Mitomycins. Mitomycin. Antibiotics, Antineoplastic. Antineoplastic Agents. Alkylating Agents. Molecular Mechanisms of ...
Patients meeting protocol criteria enrolled with malignant ascites.. Drug: mitomycin C Mitomycin C is infused into the ... Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites. The safety and scientific ... Mitomycins. Mitomycin. Antibiotics, Antineoplastic. Antineoplastic Agents. Alkylating Agents. Molecular Mechanisms of ... This phase II trial is studying how well mitomycin works when given as a hyperthermic peritoneal perfusion in treating patients ...
Patients undergo complete resection of tumor on day 0. Patients then receive mitomycin. intraperitoneally (IP) over 23 hours on ... mitomycin vs systemic fluorouracil alone in terms of survival in patients with peritoneal. cancer originating from the ... Patients are followed. every 3 months for 2 years.. PROJECTED ACCRUAL: At least 90 patients (45 per arm) will be accrued for ... Patients are stratified according to. center and mode of surgery. Patients are randomized to one of two treatment arms. Arm I: ...
Experimental: Arm I (mitomycin C) Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC. ... Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix. The safety and scientific validity of ... Arm I: Patients undergo surgical cytoreduction and receive mitomycin C by hyperthermic intraperitoneal chemotherapy (HIPEC). ... Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C ...
Mitomycin C is infused into the. abdominal cavity by hyperthermic perfusion over 60 minutes.. Quality of life is assessed at ... Patients undergo laparoscopic surgery to remove ascitic fluid and any intraabdominal. adhesions and to place 2 inflow and 2 ... Determine any improvement in the quality of life of patients treated with this. procedure.. OUTLINE: This is a nonrandomized ... Determine the effectiveness of laparoscopic hyperthermic perfusion of mitomycin C in. preventing relapse at 4 weeks post- ...
... and capecitabine in pretreated patients with metastatic or locally advanced... ... Purpose We conducted a multicenter phase II study to assess the toxicity and efficacy of a combination of mitomycin C (MMC) ... Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. ... Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced ...
The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma. The safety and ... For patients with metastatic liver cancer or HCC, some studies have discussed the effectiveness of 5-fluorouracil/mitomycin(FM ... The aim of this study is to evaluate the efficacy of 5-fluorouracil + Mitomycin for the patients with pulmonary metastasis of ... The aim of this study is to evaluate the efficacy of 5-fluorouracil/mitomycin for the patients with pulmonary metastasis of ...
Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG). ... Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) ... Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non ... Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non ...
Two patients (5.5%) on the CAC treatment arm (95% confidence interval [CI], 0% to 15%) and four patients (10.2%) on the SMF ... A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and ... Seven of 18 patients with measurable disease in this Phase I trial had partial responses to CAC. A Phase III comparison of CAC ... Eighty-two patients with advanced PC were entered into this random assignment trial. The two treatment arms were well balanced ...
Get up-to-date information on Mitomycin side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about ... and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time ... Mitomycin can also be used during glaucoma surgery.. Mitomycin is an antibiotic. It slows or stops the growth of cells, ... Mitomycin can also cause blurred vision and drowsiness. Do not drive or operate heavy machinery until you know how mitomycin ...
... of patients received the full dose of chemotherapy with capecitabine and mitomycin without interruption. Five patients ... Mitomycin. Administer mitomycin (vesicant):. *over 15 minutes *via a minibag OR. *by IV bolus via a side port of a freely ... Patients and carers*Anticancer drug treatments*Radiotherapy treatments*Cancer genetics consumer information sheets*Patient ... The rate of complete response at 4 weeks was 77% (24 patients).r Partial response at 4 weeks occurred in 5 patients (16%) and 1 ...
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to ... When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to ... is there anything like that for mitomycin tx? ... into a catheter syringe after I catheterize the patient and ...
Mitomycin-C in given with the first and second course only. Patients responding to treatment or with stable disease are ... All patients receive chemotherapy with MVP (mitomycin-C, vinblastine and moderate dose cisplatin) repeated every 21 days for ... 5. Patients must already have achieved symptom relief after three cycles of MVP chemotherapy. 6. No uncontrolled infection 7. ... Mitomycin-C is given with the first and third course only.. 2. Arm B: Best supportive care. ...
A solution containing 12.5 mg/mL of indocyanine green was added to mitomycin C, resulting in an mitomycin C concentration of ... A total of 37 eyes of 37 patients followed up for 1 year. ... green as a surgical dye in trabeculectomy with mitomycin C.. ... To investigate the effect of adding indocyanine green to mitomycin C in augmented trabeculectomy. ...
In a case series of three patients, two women [aged 61-74-years] were described, who developed transient corneal epithelial ... Latanoprost/mitomycin. Transient corneal epithelial bullae, ocular surface toxicity and limbal stem cell deficiency: 2 case ... An event is serious (based on the ICH definition) when the patient outcome is:. *. * death ... bullae, ocular surface toxicity or limbal stem cell deficiency following treatment with mitomycin [mitomycin-C] or latanoprost ...
Patients were classified into four groups: Group I, on-flap without MMC, 181 eyes; Group II, on-flap with MMC, 52 eyes; Group ... Methods In this non-randomised comparative retrospective study, the charts of 198 patients (394 eyes) who had undergone an epi- ... Clinical outcomes of epi-LASIK: 1-year results of on- and off-flap procedures with and without mitomycin-C ... Clinical outcomes of epi-LASIK: 1-year results of on- and off-flap procedures with and without mitomycin-C ...
Find out more about how it is given and possible side effects of mitomycin. ... Mitomycin is also known as Mitomycin C Kyowa®. It is used to treat many different types of cancer. ... They talk about what to bring to treatment, side effects and friendship between patients. ... What is mitomycin (Mitomycin C Kyowa®)?. Mitomycin (Mitomycin C Kyowa®) is a chemotherapy drug used to treat different cancers ...
Mitomycin: learn about side effects, dosage, special precautions, and more on MedlinePlus ... AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists®, 4500 East-West ... Before receiving mitomycin,. *tell your doctor and pharmacist if you are allergic to mitomycin, any other medications, or any ... Mitomycin comes as a powder to be mixed with liquid and injected intravenously (into a vein) by a doctor or nurse in a medical ...
Mitomycin Pyelocalyceal: learn about side effects, dosage, special precautions, and more on MedlinePlus ... AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists®, 4500 East-West ... Before receiving mitomycin pyelocalyceal,. *tell your doctor and pharmacist if you are allergic to mitomycin, any other ... Mitomycin is in a class of medications called anthracenediones (anticancer antibiotics). Mitomycin pyelocalyceal treats cancer ...
The patient suffered usual side effects of Mitomycin, including self-limited fatigue, dysuria, daytime urinary frequency up to ... Intraurethral Mitomycin C is Possible. We report the successful application of Mitomycin C to urethral carcinoma, by a method ... The patient was taken to the operating room for a third excision, where several urethral tumors were removed. Pathology showed ... The patient is currently disease-free more than one year and three months posttreatment. This case highlights the successful ...
Mitomycin (Mutamycin) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of ... This is a rare event seen in less than 2 % of patients treated with mitomycin, it can occur at any time but usually seen after ... Mutamycin is the trade name for mitomycin. MTC and Mitomycin-C are other names for mitomycin. In some cases, health care ... These side effects are less common side effects (occurring in about 10-29%) of patients receiving mitomycin: ...
T1 - Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal ... Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal ... Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal ... Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal ...
  • Aim To evaluate and compare the clinical outcomes of epi-laser in situ keratomileusis (LASIK) performed either on-flap or off-flap with or without 0.02% mitomycin-C (MMC) in terms of corneal haziness, pain scores and satisfaction scores. (bmj.com)
  • To investigate the inhibitory effect of 0.02% mitomycin C on eyelash regrowth when injected to the eyelash hair follicle immediately after radiofrequency ablation. (bvsalud.org)
  • Twenty eyes of 14 patients were treated with 0.02% mitomycin C to the hair follicle immediately after radiofrequency ablation in group 1, while radiofrequency ablation only was conducted in ten eyes of seven patients in group 2. (bvsalud.org)
  • Following topical chemotherapy with 0.02% Mitomycin (MMC) drops administered daily for 2 minutes during 14 days. (escrs.org)
  • The chief problem in treating urethral carcinoma is how to expose the urethra to topical chemotherapy agents such as BCG or Mitomycin C. We present a case illustrating how to place chemotherapy effectively in the urethra, to curative effect in a patient with multiple previous failures of simple fulgaration. (hindawi.com)
  • Prospective study of the effect of topical application of Mitomycin C in refractory pediatric. (deepdyve.com)
  • Topical Mitomycin C (MMC) has been recently used in the management of resistant strictures. (deepdyve.com)
  • All patients were randomly divided into two equal groups using the research randomizer program (1:1 randomization), group I underwent endoscopic dilatation therapy only and group II underwent dilatation with topical appli- cation of MMC. (deepdyve.com)
  • Topical treatments identified include imiquimod, mitomycin C and plant extracts such as onion extract, green tea, Aloe vera , vitamin E and D, applied to healing wounds, mature scar tissue or fibrotic scars following revision surgery, or in combination with other more established treatments such as steroid injections and silicone. (springer.com)
  • Their influence and feedback are essential to effective nurse preparation in settings where high turnover can impact patient outcomes. (oncologynurseadvisor.com)
  • ASCRS empowers Anterior Segment Surgeons to improve the vision, outcomes and quality of life for their patients through innovative approaches to Education, Advocacy and Philanthropy. (ascrs.org)
  • While all professional disciplines clearly reported grave concerns regarding the risk of adverse patient outcomes during drug shortages, physicians reported encountering this risk more frequently than others, preceded in frequency only by lack of information about the causes and duration of shortages and lack of advanced warning from manufacturers or FDA. (ismp.org)
  • About one in four reported actual errors and one in five reported adverse patient outcomes during the past year due to drug shortages. (ismp.org)
  • However, many respondents repeatedly commented that errors and adverse patient outcomes were not shared with them on a routine basis, were based on sporadic voluntary reporting, or were difficult to quantify. (ismp.org)
  • Respondents provided disquieting details regarding actual near misses, errors, and adverse patient outcomes associated with more than 50 drugs that had abruptly become unavailable, often without adequate notice. (ismp.org)
  • Dose-painting IMRT with 5-FU and mitomycin-C for anal canal cancer is associated with significant sparing of grade 3+ dermatologic and gastrointestinal acute toxicity without compromising two-year outcomes," Lisa Kachnic, MD, of Boston University, said at a news briefing prior to the symposium. (medpagetoday.com)
  • Thus, elucidation of factors leading to a second cancer and methods to avoid it may have substantial impact on both individual patient outcomes and public health. (biomedcentral.com)
  • His research has now expanded to include better intraoperative imaging modalities in pediatric patients to improve surgical outcomes without the need for radiation exposure. (stanford.edu)
  • Specific goals of this guideline are to promote best practices, reduce unjustified variations in care of patients with nosebleeds, improve health outcomes, and minimize the potential harms of nosebleeds or interventions to treat nosebleeds. (stanford.edu)
  • Advanced age and female sex have been associated with worse outcomes in patients undergoing radical cystectomy for muscle-invasive bladder cancer. (urotoday.com)
  • This study compared the efficacy and safety of suberoylanilide hydroxamic acid (SAHA) and mitomycin C (MMC) up to 4 months in the prevention of corneal haze induced by photorefractive keratectomy (PRK) in rabbits in vivo. (healio.com)
  • Agents capable of limiting keratocyte proliferation or differentiation after photorefractive keratectomy (PRK) are effective in preventing myofibroblast formation and corneal haze appearance in preclinical animal models and human patients. (healio.com)
  • Cardiac alarm monitoring optimization using evidence-based widened parameters can ease alarm fatigue for nurse staff and provide a safer, quieter environment for patients, according to a presentation at the National Association of Certified Nurse Specialists (NACNS) 2018 Annual Meeting. (oncologynurseadvisor.com)
  • This is not a complete list of mitomycin drug interactions. (medicineshoppe.com)
  • The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many antineoplastic drugs are reimbursed on the PBS. (eviq.org.au)
  • This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML an. (bioportfolio.com)
  • Mitomycin (Mitomycin C Kyowa ® ) is a chemotherapy drug used to treat different cancers including breast, bladder, gullet (oesophagus), stomach, pancreas, lung, anal and liver cancers. (macmillan.org.uk)
  • Mitomycin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. (chemocare.com)
  • The effect of chemotherapy drug Mitomycin C (MMC) in combination with recombinant adeno-associated virus II (rAAV2) in cancer therapy was investigated, and the mechanism of MMC affecting rAAV2's bioactivity was also studied. (mdpi.com)
  • A study conducted by a surgical team at Creighton University Medical Center in Omaha, Nebraska published April 8, 2014, has shown what researchers believe is the correct chemotherapy drug to use in conjunction with surgery in patients suffering from peritoneal mesothelioma, reports the national law firm of Baron and Budd. (prweb.com)
  • Prompt measures such as discontinuation or modification of chemotherapy or use of appropriate drug therapy should be initiated on the basis of changes in monitoring parameters before the patient exhibits signs and symptoms of cardiotoxicity. (lymphomation.org)
  • An exhaustive account of frustrations, difficulties, and patient safety concerns came across loud and clear from more than 1,800 healthcare practitioners (68% pharmacists) who participated in our July-September 2010 survey on drug shortages. (ismp.org)
  • Furthermore, combining eye drops may improve patient adherence to the drug regimen by decreasing the frequency of administration. (dovepress.com)
  • The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company led drug recall, to be actioned, for certain batches of: Mitomycin-C. (psnc.org.uk)
  • Subanalyses pooled studies by drug type and a meta-regression was performed to determine the effect of underlying patient risk factors on the efficacy of a single dose of IVC. (jnccn.org)
  • In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. (jnccn.org)
  • The use of vinorelbine in combination with another anticancer drug, mitomycin-C , has caused severe shortness of breath. (encyclopedia.com)
  • Patients taking vinorelbine and another anticancer drug, paclitaxel , may be more likely to experience toxicity of the nervous system , and should be carefully monitored for this. (encyclopedia.com)
  • The researchers treated drug-resistant cells with a low dose of the cancer drug mitomycin C, waited 24 hours, then administered a second chemotherapy agent. (eurekalert.org)
  • Number of patients with grade 3 or 4 acute toxicities (excluding grade 3 or 4 urinary toxicities) that are related to study drug, graded according to CTCAE v4.03. (anzctr.org.au)
  • Methods: A total of 53 lesions from 43 patients with bladder cancer confirmed by postoperative pathology were retrospectively analyzed, including 27 cases of high-grade urothelial carcinoma (HGUC) and 26 cases of low-grade urothelial carcinoma (LGUC). (urotoday.com)
  • In 2004, Sylvester et al 3 performed a meta-analysis of 7 randomized clinical trials (RCTs) comparing cancer recurrence rates in patients undergoing TUR alone against a combination of TUR and a single immediate postoperative dose of IVC. (jnccn.org)
  • One interesting thing noted by the investigators is that almost a third of patients failed within the first postoperative year. (ophthalmologytimes.com)
  • This randomized phase II trial is studying the side effects and how well giving oxaliplatin or mitomycin C directly into the abdomen after surgery works in treating patients with tumors of the appendix. (clinicaltrials.gov)
  • Seven of 18 patients with measurable disease in this Phase I trial had partial responses to CAC. (uni-bonn.de)
  • Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. (openrepository.com)
  • The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of TAB08 when administered intravenously (i.v.) to patients with advanced solid malignancies. (bioportfolio.com)
  • A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. (bioportfolio.com)
  • This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in treating patients with advanced or refractory solid tumors. (mayo.edu)
  • This phase II trial studies how well atezolizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body and cannot be removed by surgery. (cancer.gov)
  • In a multicenter phase III trial, it did not improve disease-free survival compared with conventional mitomycin-based chemotherapy and led to a significantly higher colostomy rate, Jaffer A. Ajani, M.D., of the University of Texas M. D. Anderson Cancer Center, and colleagues, reported in the April 23 issue of the Journal of the American Medical Association . (medpagetoday.com)
  • The syndrome may occur at any time during therapy with mitomycin, but most cases occur at doses greater than or equal to 60 mg. (drugs.com)
  • Mitomycin is a prescription medication used to treat cancer of the stomach or pancreas that has spread to other parts of the body and has not improved with other medications, surgery, or radiation therapy. (medicineshoppe.com)
  • The combination therapy of MAP followed by Bleomycin and CCNU for patients with advanced anal cancer, not amenable to radiotherapy or surgery, results in a moderate objective response but with moderate toxicities. (elsevier.com)
  • This regimen and sequence is worthy of further study especially in combination with colony stimulating factors, however, its tolerability may be most applicable for patients who have had minimal prior therapy. (elsevier.com)
  • Which patients with myelofibrosis should receive ruxolitinib therapy? (nature.com)
  • This is a rare event seen in less than 2 % of patients treated with mitomycin, it can occur at any time but usually seen after several cycles of therapy. (chemocare.com)
  • Lastly, 24 h after administration of clearing agent, patients received biotin-DOTA-labeled with 110 mCi/m 2 90 Y. All three components of the therapy were administered i.v. Both hematological and nonhematological toxicities were observed. (aacrjournals.org)
  • 2) Patients must have failed conventional therapy for their cancer or have a malignancy for which a conventional therapy does not exist. (mdanderson.org)
  • In this study, patients with advanced epithelial cancer of the anal canal received MAP followed by Bleomycin and CCNU upon progression of disease. (elsevier.com)
  • Patients treated by liver resection had the best outcome, while patients with extrahepatic diseases had poor prognosis. (nih.gov)
  • To determine whether patients with locally advanced non-small cell lung cancer unsuitable for resection or radical radiotherapy, and with minimal thoracic symptoms, should be given palliative thoracic radiotherapy immediately or as needed to treat symptoms. (bmj.com)
  • 230 patients with previously untreated, non-small cell lung cancer that is locally too advanced for resection or radical radiotherapy with curative intent, with minimal thoracic symptoms, and with no indication for immediate thoracic radiotherapy. (bmj.com)
  • Where patient has only had a biopsy/partial resection and is otherwise eligible for entry into the study, the case should be rediscussed with the referring urologist to see whether further resection would be feasible prior to embarking with the chemo-radiotherapy. (anzctr.org.au)
  • Twenty-one patients were treated with actinomycin D and 22 with mitomycin C. The principal toxic effects of actinomycin D were ulceration of the mouth and pharynx, nausea, and dermatitis, while the main toxic effect of mitomycin C was bone marrow depression. (umn.edu)
  • PVOD may occur in patients with associated diseases such as HIV, bone marrow transplantation, and connective tissue diseases. (wikipedia.org)
  • Tell your doctor if you have ever had any unusual or allergic reaction to mitomycin or any other medicines. (drugs.com)
  • Allergic contact dermatitis following ophthalmic administration in an elderly patient: case report. (ebscohost.com)
  • 3. To measure the plasma pharmacokinetics of LOC-paclitaxel and paclitaxel derived from LOC-paclitaxel in patients receiving escalating doses of weekly LOC-paclitaxel. (mdanderson.org)
  • Methods In this non-randomised comparative retrospective study, the charts of 198 patients (394 eyes) who had undergone an epi-LASIK procedure for myopia (−1.5 D to −8.0 D spherical equivalent) correction were reviewed. (bmj.com)
  • Methods: This was a comparative, population-based cohort study of all Dutch patients diagnosed with synchronous colorectal PM who underwent CRS-HIPEC between 2014 and 2017. (vumc.nl)
  • Methods: Twenty-four consecutive patients with synchronous renal cell carcinoma and urothelial carcinoma treated in our center from March 2005 to December 2015 were retrospectively reviewed. (urotoday.com)
  • Methods Primary cultures of HNMFs were established from nasal mucosal tissues of patients undergoing DCR. (bmj.com)